Carisma Therapeutics Inc. (CARM) presented promising preclinical data on engineered macrophages for treating liver fibrosis at the ...

Accumulation of extracellular matrix (ECM) in liver fibrosis is associated with changes in protein abundance and composition depending upon etiology of the underlying liver disease. Current efforts to ...

About Hydronidone (F351) F351 is a structural analogue of the approved anti-fibrotic (IPF) drug Pirfenidone and has been shown to inhibit in vitro both p38γ kinase activity and TGF-β1-induced ...

SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic ...

Learn about HMGB1's crucial role in liver diseases, its pathways and therapeutic potential that can treat liver diseases.

This review discussed experimental mouse models used in the pre-clinical study of liver fibrosis regression, a pivotal ...

Liver diseases, both acute and chronic, continue to pose significant clinical challenges due to high morbidity and mortality ...

Additionally, in liver fibrosis, HMGB1 activates hepatic stellate cells (HSCs), contributing to the fibrotic response, while ...

The rate of progression of fibrosis in an individual patient with chronic liver disease cannot be predicted with certainty. However, some general rules apply, as discussed below. 4. The precise ...